Calidi presents new data on CLD-401 at AACR

Calidi (CLDI) Biotherapeutics will present new data at the American Association of Cancer Research, AACR, annual meeting in San Diego, California on April 21 2026. The Company showcased new data on CLD-401, a systemically delivered oncolytic virus that is designed to express high levels of IL-15 superagonist only in the tumor microenvironment, currently in IND-enabling studies. The Company expects to file an IND for CLD-401 by the end of 2026. Data at AACR detailed the immune changes in the TME induced by CLD-401 including the recruitment and activation of NK, NK-T, and gamma delta (gammadelta) T-cells that lead to a therapeutic response in the immunocompetent animal models. In addition to IL-15 SA delivery with CLD-401, the RedTail platform has also been shown to enable in situ expression of tumor-targeted T cell engagers, as demonstrated in a separate AACR presentation focused on the CLD-501 program